欧洲对创伤后急性大出血和凝固性凝血病管理的观点:2019年更新的欧洲指南摘要

2021-02-28 0 J Clin Med . 2021 Jan 19;10(2):362

伴有创伤诱发性凝血病(TIC)的非控制性出血仍然是多发伤后可预防死亡的最常见原因。快速识别并积极治疗是改善预后的关键。创伤性出血的治疗始于现场,需要手动加压,使用止血带和(非)商品骨盆吊带,并迅速转移

中文标题:

欧洲对创伤后急性大出血和凝固性凝血病管理的观点:2019年更新的欧洲指南摘要

英文标题:

The European Perspective on the Management of Acute Major Hemorrhage and Coagulopathy after Trauma: Summary of the 2019 Updated European Guideline

发布机构:

0

发布日期:

2021-02-28

简要介绍:

伴有创伤诱发性凝血病(TIC)的非控制性出血仍然是多发伤后可预防死亡的最常见原因。快速识别并积极治疗是改善预后的关键。创伤性出血的治疗始于现场,需要手动加压,使用止血带和(非)商品骨盆吊带,并迅速转移至适当的创伤中心。入院后应立即开始凝血监测和支持。出血是根据损伤控制原则通过手术控制的。现代凝血管理包括在护理点粘弹性测定法的指导下进行的面向目标的个性化治疗。 Idarucizumab可用作凝血酶抑制剂达比加群的解毒剂,exanetα可用作因子Xa抑制剂的解毒剂。这篇综述总结了2019年更新的欧洲指南中有关创伤后重大出血和凝血病管理的主要建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=f129c1c002059899, title=欧洲对创伤后急性大出血和凝固性凝血病管理的观点:2019年更新的欧洲指南摘要 , enTitle=The European Perspective on the Management of Acute Major Hemorrhage and Coagulopathy after Trauma: Summary of the 2019 Updated European Guideline, guiderFrom=J Clin Med . 2021 Jan 19;10(2):362, authorId=0, author=, summary=伴有创伤诱发性凝血病(TIC)的非控制性出血仍然是多发伤后可预防死亡的最常见原因。快速识别并积极治疗是改善预后的关键。创伤性出血的治疗始于现场,需要手动加压,使用止血带和(非)商品骨盆吊带,并迅速转移, cover=, journalId=0, articlesId=null, associationId=null, associationName=0, associationIntro=, copyright=0, guiderPublishedTime=Sun Feb 28 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span class="VIiyi" lang="zh-CN"><span class="JLqJ4b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0">伴有创伤诱发性凝血病(TIC)的非控制性出血仍然是多发伤后可预防死亡的最常见原因。快速识别并积极治疗是改善预后的关键。创伤性出血的治疗始于现场,需要手动加压,使用止血带和(非)商品骨盆吊带,并迅速转移至适当的创伤中心。入院后应立即开始凝血监测和支持。出血是根据损伤控制原则通过手术控制的。现代凝血管理包括在护理点粘弹性测定法的指导下进行的面向目标的个性化治疗。 Idarucizumab可用作凝血酶抑制剂达比加群的解毒剂,exanet&alpha;可用作因子Xa抑制剂的解毒剂。这篇综述总结了2019年更新的欧洲指南中有关创伤后重大出血和凝血病管理的主要建议。</span></span></p>, tagList=[TagDto(tagId=756, tagName=创伤)], categoryList=[CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=14745, appHits=167, showAppHits=0, pcHits=986, showPcHits=14578, likes=3, shares=15, comments=12, approvalStatus=1, publishedTime=Sun Feb 14 09:56:14 CST 2021, publishedTimeString=2021-02-28, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Sat Feb 13 21:32:08 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Thu Jan 04 16:50:25 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击:
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1012074, encodeId=efdc10120e45a, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210827/4a5b71e0f1bf4e1d8a4ec64afb8fe2cc/9e96715d1c7145afb8f586dec1e712a8.jpg, createdBy=f26a5586851, createdName=ms4000002121232761, createdTime=Fri Aug 27 15:33:41 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008520, encodeId=480e1008520eb, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94325245319, createdName=147ccf36m07暂无昵称, createdTime=Tue Aug 17 00:33:29 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001023, encodeId=02a0100102359, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e441336471, createdName=lujieyy, createdTime=Tue Jul 20 07:35:17 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996116, encodeId=471699611637, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210704/95a6dce31e174b2da437bbf0d7090c4c/18a48c44e42e4055ad2157fc5a9a4353.jpg, createdBy=b8865528278, createdName=litlco, createdTime=Sun Jul 04 15:50:03 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970635, encodeId=58089e0635b3, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/643a7d9f97e14784b5cd2cf62f4b6f2c/867c9610944e474ba12ff29881da25e0.jpg, createdBy=fd345226472, createdName=睿宣, createdTime=Thu Jun 03 17:24:13 CST 2021, time=2021-06-03, status=1, ipAttribution=)]
    2021-08-27 ms4000002121232761

    不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1012074, encodeId=efdc10120e45a, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210827/4a5b71e0f1bf4e1d8a4ec64afb8fe2cc/9e96715d1c7145afb8f586dec1e712a8.jpg, createdBy=f26a5586851, createdName=ms4000002121232761, createdTime=Fri Aug 27 15:33:41 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008520, encodeId=480e1008520eb, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94325245319, createdName=147ccf36m07暂无昵称, createdTime=Tue Aug 17 00:33:29 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001023, encodeId=02a0100102359, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e441336471, createdName=lujieyy, createdTime=Tue Jul 20 07:35:17 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996116, encodeId=471699611637, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210704/95a6dce31e174b2da437bbf0d7090c4c/18a48c44e42e4055ad2157fc5a9a4353.jpg, createdBy=b8865528278, createdName=litlco, createdTime=Sun Jul 04 15:50:03 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970635, encodeId=58089e0635b3, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/643a7d9f97e14784b5cd2cf62f4b6f2c/867c9610944e474ba12ff29881da25e0.jpg, createdBy=fd345226472, createdName=睿宣, createdTime=Thu Jun 03 17:24:13 CST 2021, time=2021-06-03, status=1, ipAttribution=)]
    2021-08-17 147ccf36m07暂无昵称

    关注

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1012074, encodeId=efdc10120e45a, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210827/4a5b71e0f1bf4e1d8a4ec64afb8fe2cc/9e96715d1c7145afb8f586dec1e712a8.jpg, createdBy=f26a5586851, createdName=ms4000002121232761, createdTime=Fri Aug 27 15:33:41 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008520, encodeId=480e1008520eb, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94325245319, createdName=147ccf36m07暂无昵称, createdTime=Tue Aug 17 00:33:29 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001023, encodeId=02a0100102359, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e441336471, createdName=lujieyy, createdTime=Tue Jul 20 07:35:17 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996116, encodeId=471699611637, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210704/95a6dce31e174b2da437bbf0d7090c4c/18a48c44e42e4055ad2157fc5a9a4353.jpg, createdBy=b8865528278, createdName=litlco, createdTime=Sun Jul 04 15:50:03 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970635, encodeId=58089e0635b3, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/643a7d9f97e14784b5cd2cf62f4b6f2c/867c9610944e474ba12ff29881da25e0.jpg, createdBy=fd345226472, createdName=睿宣, createdTime=Thu Jun 03 17:24:13 CST 2021, time=2021-06-03, status=1, ipAttribution=)]
    2021-07-20 lujieyy

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1012074, encodeId=efdc10120e45a, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210827/4a5b71e0f1bf4e1d8a4ec64afb8fe2cc/9e96715d1c7145afb8f586dec1e712a8.jpg, createdBy=f26a5586851, createdName=ms4000002121232761, createdTime=Fri Aug 27 15:33:41 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008520, encodeId=480e1008520eb, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94325245319, createdName=147ccf36m07暂无昵称, createdTime=Tue Aug 17 00:33:29 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001023, encodeId=02a0100102359, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e441336471, createdName=lujieyy, createdTime=Tue Jul 20 07:35:17 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996116, encodeId=471699611637, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210704/95a6dce31e174b2da437bbf0d7090c4c/18a48c44e42e4055ad2157fc5a9a4353.jpg, createdBy=b8865528278, createdName=litlco, createdTime=Sun Jul 04 15:50:03 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970635, encodeId=58089e0635b3, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/643a7d9f97e14784b5cd2cf62f4b6f2c/867c9610944e474ba12ff29881da25e0.jpg, createdBy=fd345226472, createdName=睿宣, createdTime=Thu Jun 03 17:24:13 CST 2021, time=2021-06-03, status=1, ipAttribution=)]
    2021-07-04 litlco

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1012074, encodeId=efdc10120e45a, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210827/4a5b71e0f1bf4e1d8a4ec64afb8fe2cc/9e96715d1c7145afb8f586dec1e712a8.jpg, createdBy=f26a5586851, createdName=ms4000002121232761, createdTime=Fri Aug 27 15:33:41 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008520, encodeId=480e1008520eb, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94325245319, createdName=147ccf36m07暂无昵称, createdTime=Tue Aug 17 00:33:29 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001023, encodeId=02a0100102359, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e441336471, createdName=lujieyy, createdTime=Tue Jul 20 07:35:17 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996116, encodeId=471699611637, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210704/95a6dce31e174b2da437bbf0d7090c4c/18a48c44e42e4055ad2157fc5a9a4353.jpg, createdBy=b8865528278, createdName=litlco, createdTime=Sun Jul 04 15:50:03 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970635, encodeId=58089e0635b3, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210603/643a7d9f97e14784b5cd2cf62f4b6f2c/867c9610944e474ba12ff29881da25e0.jpg, createdBy=fd345226472, createdName=睿宣, createdTime=Thu Jun 03 17:24:13 CST 2021, time=2021-06-03, status=1, ipAttribution=)]
    2021-06-03 睿宣

    很好

    0